Review

Nature Reviews Immunology 6, 383-393 (May 2006) | doi:10.1038/nri1842

Focus on: Translational immunology

Adoptive immunotherapy for cancer: building on success

Luca Gattinoni1,2, Daniel J. Powell, Jr.1,2, Steven A. Rosenberg2 & Nicholas P. Restifo2  About the authors

Top

Adoptive cell transfer after host preconditioning by lymphodepletion represents an important advance in cancer immunotherapy. Here, we describe how a lymphopaenic environment enables tumour-reactive T cells to destroy large burdens of metastatic tumour and how the state of differentiation of the adoptively transferred T cells can affect the outcome of treatment. We also discuss how the translation of these new findings might further improve the efficacy of adoptive cell transfer through the use of vaccines, haematopoietic-stem-cell transplantation, modified preconditioning regimens, and alternative methods for the generation and selection of the T cells to be transferred.

Author affiliations

  1. These authors contributed equally to this work.
  2. National Cancer Institute, National Institutes of Health, Mark O. Hatfield Clinical Research Center, Room 3-5762, 10 Center Drive, Bethesda, Maryland 20892-1201, USA.

Correspondence to: Luca Gattinoni1,2 Email: gattinol@mail.nih.gov

Correspondence to: Nicholas P. Restifo2 Email: restifo@nih.gov

Published online 18 April 2006

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

Extra navigation

Subscribe

Subscribe to Nature Reviews Immunology

Open Innovation Challenges

naturejobs

Advertisement